Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US - GBI Research Reports

Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US

Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US - GBI Research Reports
Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US
Published Dec 31, 2011
103 pages — Published Dec 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US which provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Poland. The report provides a comprehensive insight of the reasons for outsourcing clinical trials to Poland and the key services provided by the Clinical Research Organizations (CROs) of Poland. The report provides a detailed analysis of the Polish market in terms of its size, and major service offerings of the CROs in Poland. The report also discusses the factors that are driving the clinical trial market in Poland. The report delves into the key documents required by the investigator and the sponsor before, during and after the conduct of clinical trials. The report also provides key alliances in the CRO market. Furthermore, the report looks into the major challenges that can restrict the growth of the clinical trials market in Poland.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

With increasing cost-cutting pressures due to decreasing Research and Development (R&D) productivity, the patent expiries of blockbusters, drying pipelines and stringent regulations of governments, the cost of conducting research in the Western world is increasing and in turn is putting immense financial pressures on the major pharmaceutical companies. On the other hand, Poland is becoming an attractive location for conducting clinical research. Speed of patient recruitment and quality of clinical trial data are two major advantages in Poland. Moreover, improvements in clinical trial regulation could drive the market in the future. Although Poland controls a very small part of the global clinical research, this share is expected to rise in the future as the Western pharmaceuticals have realized the need to outsource the maximum possible amount of R&D work to low-cost countries. With clinical studies occupying the majority of R&D costs, there is a huge opportunity for significant cost savings.

However, developed countries will face several challenges to continue their growth momentum. Legislative drawbacks and a lack of social awareness towards clinical trials will be the major obstacles for companies in Poland. Moreover, increasing competition from other Eastern European countries is also expected to impede the growth of the clinical trial market in Poland.

Scope

- The need for outsourcing clinical trials to Poland.
- Trends in clinical trial registration in Poland and a comparative analysis of clinical trial registration in Eastern European countries.
- Analysis of the key drivers that are fueling the growth of the clinical trial market in Poland.
- Analysis of the key infrastructural facilities, clinical research professionals and principal investigators in Poland.
- Analysis of key government regulations in Poland affecting the clinical trial market.
- Study of 12 major CROs operating in Poland.

Reasons to buy

- Compare the key capabilities of major clinical trial service providers with your requirements and optimize your R&D costs.
- Develop market entry and market expansion strategies by identifying the key drivers and challenges in the Polish clinical trials market.
- Develop effective strategies to maximize the advantages in Poland through understanding of the regulatory environment.
- Understand the regulatory structure in Poland and key documents required to register clinical trials in Poland.

  
Source:
Document ID
GBIHC138MR
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables52
  List of Figures72
Emerging Market for Clinical Trials - Poland - Introduction91
  GBI Research Report Guidance91
Emerging Market for Clinical Trials - Poland - Overview1016
  The Clinical Research Process- Overview101
    Drug Discovery111
    Preclinical Study/Development111
    Clinical Trials111
      The Phases of a Clinical Trial121
  Clinical Trial Design and Types131
    Types of Design131
      Parallel Group Trial Design131
      Cross over Trial Design141
      Adaptive Clinical Trial Design152
      Wyeth s Learn &Confirm Model172
  Role of CROs191
  Sponsors of Clinical Trials201
  The Need for Outsourcing Clinical Trials211
    High Risks and Costs Associated With Drug Development211
    Escalating Costs of Clinical Trials221
    Global Increase in the Number of Clinical Trials Conducted231
    Restructuring the R&D241
    Increased Screening Rates during R&D251
    Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs251
Emerging Market for Clinical Trials - Poland - Clinical Trial Trends2623
  Clinical Trials Registered Globally261
  Clinical Trials Registered in Eastern European Countries272
  Analysis of Clinical Trials Registered in Poland291
    Clinical Trials Registered in 1995-2010292
    Analysis of Clinical Trials Registered in 2010311
    Registration of Phase l Clinical Trials321
    Registration of Phase ll Clinical Trials331
    Registration of Phase lll Clinical Trials341
    Registration of Phase lV Clinical Trials351
    Clinical Trials Registered by Therapeutic Area361
  Comparative Analysis of Industry Sponsored Clinical Trials Registered in US Trials Registry in the Eastern Europe Countries371
  Analysis of Clinical Trials Registered by MNCs in Poland382
  Sites for Industry Sponsored Clinical Trials Worldwide402
  Sites for Industry Sponsored Clinical Trials Registered in Eastern European Countries421
    Number of Registered Sites for Industry Sponsored Clinical Trials (Phase II/III)421
    Number of Multi-national Sites Registered for Industry Sponsored Trials (Phase II/III)431
      Number of Multinational Sites Registered for Industry Sponsored Phase II Trials441
      Number of Multi-national Sites Registered for Industry Sponsored Phase III Trials451
    Number of Local Sites Registered for Industry Sponsored Trials (Phase II/III)461
      Number of Local Sites Registered for Industry Sponsored Phase II Trials471
      Number of Local Sites Registered for Industry Sponsored Phase III Trials481
Emerging Market for Clinical Trials - Poland - Market Environment Characterization4926
  Global CRO Market491
    Pipeline Analysis of Five Major Pharmaceutical Companies501
  Clinical Trial Market in Poland512
  Key Drivers of Clinical Trials Market in Poland531
    Population Statistics531
      Comparison of Population between Eastern European Countries531
      Population Forecast of Poland542
    Patient Availability for Major Diseases561
      Number of Deaths Occurring by Major Diseases in Poland561
      HIV/AIDS571
      Diabetes581
      Cancer591
    Patient Recruitment and Speed of Trials601
      Patients per Clinical Trial Worldwide601
      Patients per Clinical Trial in Eastern European Countries611
      Patients per Clinical Trial in Poland621
      Patients per Trial Site in Eastern European Countries631
      Patients per Trial Site in Poland641
    Patients and Clinical Trial Sites Density651
      Patients per Million Population in Eastern European Countries651
      Clinical Trial Sites per Million Population in Eastern European Countries661
    Qualified and Experienced Talent Pool671
      Increase in Number of FDA Regulated Principal Investigators Worldwide671
      Increase in the Number of FDA Regulated Principal Investigators in Poland681
    Favorable Clinical Infrastructure in Poland Enhances the Clinical Trial Environment691
      Health Care Professionals Density Per 10,000 Population692
      Hospital Beds Density Per 10,000 Population711
    Comparative Analysis of Cost of Clinical Trials amongst Countries Worldwide721
    Quality of Clinical Trial Data722
  Key Restraints of Clinical Trials Market in Poland741
    Long Trial Registration Process741
    Other Restraints741
Emerging Market for Clinical Trials - Poland - Regulatory Landscape7513
  Introduction751
  Regulatory Provisions in Poland Related to Clinical Trials761
  Major Regulatory Authorities and Trial Registration Process in Poland771
    Major Regulatory Authorities in Poland771
    Authorizations and Approval Process for Clinical Trials in Poland773
  Documents to be Submitted for Conducting a Clinical Trial in Poland801
    Documents to be Submitted to the Registration Office for Conducting a Clinical Trial801
    Documents to be Submitted to the Bioethics Committee for Conducting a Clinical Trial812
    Documents Required With the Investigator and Sponsor of Clinical Trials831
      Documents to be Located in the Files of Investigator and Sponsor before the Commencement of Clinical Trials832
      Documents to be Located in the Files of Investigator and Sponsor during the Clinical Conduct of Trials851
      Documents to be Located in the Files of Investigator and Sponsor after Completion of Clinical Trials861
  Possible Regulatory Changes in Clinical Trials871
Emerging Market for Clinical Trials - Poland - CRO Landscape8810
  CRO Profiles881
    Quintiles Poland881
      Business Description881
    Covance891
      Business Desription891
    Kendle901
      Business Description901
    PPD911
      Business Description911
    Chiltern921
      Business Description921
    ICON plc.931
      Business Description931
    PRA International941
      Business Description941
    PAREXEL951
      Business Description951
    Lambda Therapeutic Research961
      Business Description961
    Synexus961
      Business Description961
    KCR961
      Business Description961
    Prosen961
      Business Description961
  Major Deals in the CRO Market971
Emerging Market for Clinical Trials - Poland - Appendix986
  Market Definitions981
  Abbreviations981
  Research Methodology994
    Coverage991
    Secondary Research991
    Primary Research991
    Expert Panel Validation1001
    Section-wise Research Methodology1001
      Clinical Trials Overview1001
      Clinical Trial Trends1001
      Market Environment Characterization1011
      Regulatory Landscape1011
      CRO landscape1021
  Contact Us1021
  Disclaimer1021
  Sources1031

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US" Dec 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Market-for-Clinical-Trials-in-Poland-Cost-Advantages-of-Nearly-30-as-Compared-to-the-US-2115-317>
  
APA:
GBI Research Reports. (2011). Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US Dec 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Market-for-Clinical-Trials-in-Poland-Cost-Advantages-of-Nearly-30-as-Compared-to-the-US-2115-317>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.